# Evelo Biosciences

Evelo Biosciences is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** evelobio.com
- **LinkedIn:** https://www.linkedin.com/company/evelo-biosciences

## Regulatory record

- **Reports private funds:** No

## About

Evelo Biosciences launched in 2015 within Flagship Pioneering's venture-creation engine, founded by CEO Simba Gill and CSO Balkrishan Gill. The wealth origin is corporate venture capital from Flagship, not a family's operating business. The firm sought to develop orally delivered monoclonal microbials — single strains of bacteria designed to engage the small intestine's immune axis and produce systemic therapeutic effects against cancer, psoriasis, and atopic dermatitis. It became a public company via a reverse merger in 2018 (per the firm's official communications). The company's strategy centered on a unique drug-discovery platform that matched specific gut-resident immune cells to disease biology. Its pipeline included EDP1815 for psoriasis and atopic dermatitis, EDP1908 for oncology, and EDP1867 for undisclosed inflammatory conditions. The geographic focus was clinical-trial execution and manufacturing in the United States and the United Kingdom, where it established research partnerships and trial sites. Evelo was a lean biotech operation with no disclosed total professionals. It maintained its research headquarters in Cambridge, Massachusetts, and operated as a single-entity public company without adjacent philanthropic foundations, family-office wealth management, or real-asset arms. The firm's structure was a conventional Delaware C-corporation with institutional venture-capital backers including Flagship Pioneering and Google Ventures. In November 2023, after multiple clinical-trial failures, Evelo announced it was exploring strategic alternatives and winding down operations, ceasing to be a going concern (per the firm's official communications). The firm's structural differentiator was its bet on monoclonal microbials as a distinct new drug modality, fully decoupled from the complex fecal-transplant or consortia-based microbiome approaches that dominated the field. This focus on a single defined bacterial strain — a "drug in a capsule" — was intended to create pharmaceutical-grade consistency, scalability, and IP protection that mixed-strain competitors could not match.

## Sectors

- Healthcare Services

## People

- Simba Gill — Chief Executive Officer
- Balkrishan Gill — Chief Scientific Officer

## Questions

### How was Evelo Biosciences capitalized before its wind-down?

Evelo went public in 2018 via a reverse merger with a publicly traded shell, and raised capital through multiple public offerings. Flagship Pioneering and GV (formerly Google Ventures) were among the largest institutional shareholders. Detailed AUM is not publicly disclosed for a biotech operating company. The firm had a limited cash runway at the time of its wind-down announcement.

## Related profiles

- [Cybersecurity Investments](https://altss.com/profile/cybersecurity-investments)
- [GateHouse Media](https://altss.com/profile/gatehouse-media)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/evelo-biosciences

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology